Connect with us

Healthcare

Cryonics: Putting Death on Ice

Published

on

Cryonic Infographic

Cryonics: Putting Death on Ice

There is a potent thread winding its way through generations of human culture. From Ancient Egyptian rituals to Kurzweil’s Singularity, many paths have sprung up leading to the same elusive destination: immortality.

Today, the concept is as popular as it’s ever been, and technological advances are giving people hope that immortality, or at very least radical life extension, may be within reach. Is modern technology advanced enough to give people a second chance through cryonics?

Today’s infographic, courtesy of Futurism, tackles our growing fascination with putting death on ice.

The Prospect of Immortality

Robert C. W. Ettinger’s seminal work, The Prospect Of Immortality, detailed many of the scientific, moral, and economic implications of cryogenically freezing humans for later reanimation. It was after that book was published in 1962 that the idea of freezing one’s body after death began to take hold.

One of the most pressing questions is, even if we’re able to revive a person who has been cryogenically preserved, will the person’s memories and personality remain intact? Ettinger posits that long-term memory is stored in the brain as a long-lasting structural modification. Basically, those memories will remain, even if the brain’s “power is turned off”.


Source

Descending into the Deep-Freeze

There are three main steps in the cryogenic process:

1) Immediately after a patient dies, the body is cooled with ice packs and transported to the freezing location.

2) Next, blood is drained from the patient’s body and replaced with a cryoprotectant (basically the same antifreeze solution used to transport organs destined for transplant).

3) Finally, once the body arrives at the cryonic preservation facility, the body is cooled to -196ºC (-320.8ºF) over the course of two weeks. Bodies are generally stored upside-down in a tank of liquid nitrogen.

The Economics of Cryopreservation

At prices ranging from about $30,000 to $200,000, cryopreservation may sound like an option reserved for the wealthy, but many people fund the procedure by naming a cryonics company as the primary benefactor of their life insurance policy. Meanwhile, in the event of a death that doesn’t allow for preservation of the body, the money goes to secondary beneficiaries.

Even if we do eventually find a way to reanimate frozen humans, another important consideration is how those people would take care of themselves financially. That’s where a cryonics or personal revival trust comes into play. A twist on a traditional dynastic trust, this arrangement ensures that there are funds to cover costs of the cryopreservation, as well as ensure the grantor would have assets when they’re unthawed. Of course, there are risks involved beyond the slim possibility of reanimation. The legal code in hundreds of years could be vastly different than today.

If you created a trust for specific purposes in 1711, it is unlikely it would function in the same way today.

– Kris Knaplund, Law Professor, Pepperdine University

Cold Humans, Hot Market

At last count, there are already 346 people in the deep freeze, with thousands more on the waiting list. As technology improves, those numbers are sure to continue rising.

Time will tell whether cryonically preserved people are able to cheat death. In the meantime? The cryonics industry is alive and well.

Click for Comments

Healthcare

Innovation in Virology: Vaccines and Antivirals

Vaccine development has grown six-fold since 1995. Learn how virology, the study of viruses, is driving innovation in the healthcare industry.

Published

on

Bar chart showing the number of vaccines approved or in development over time to highlight innovation within virology. The number of vaccines approved or in development jumped by 13% from 2020 to 2021.

Published

on

The following content is sponsored by MSCI

Innovation in Virology: Vaccines and Antivirals

The COVID-19 pandemic affected millions of people worldwide and brought renewed focus to virology—the study of viruses.

However, impact made by viruses extends far beyond the SARS-CoV-2 virus that causes COVID-19. There are 24 viruses that have each infected more than 80 million people globally, from hepatitis to influenza. 

In this graphic from MSCI, we uncover innovation in vaccines and antivirals and the related market opportunities.

What is a Virus?

A virus is a microscopic infectious agent that replicates within living cells. It may cause disease in its host. New viruses can emerge at any time as a result of mutation, or when viruses transfer from animals to humans.

Through virology, scientists are continuously finding new ways to fight against infectious diseases. Two main types of anti-infectives are available: vaccines and antivirals.

Rapid Innovation in Vaccines

Vaccines are substances designed to prevent people from getting infected with a disease or experiencing serious symptoms. 

The number of vaccines has increased dramatically over the last three decades. From 2020 to 2021 alone, the number of approved vaccines or clinical candidates jumped by 13%.

YearVaccines Approved or in Development
1995240
1996262
1997309
1998323
1999374
2000415
2001462
2002472
2003509
2004531
2005564
2006610
2007606
2008704
2009751
2010866
2011893
2012880
2013943
20141075
20151179
20161374
20171397
20181340
20191356
20201388
20211567

Data is a snapshot in time and reflects all vaccines ever approved (and not taken off the market) plus all vaccines in development as of the noted year (for which a trial has not been canceled).

Not only that, it’s possible to have shorter approval timelines. COVID-19 vaccines were approved within 11 months, much more quickly than the 2000-2020 average of 10 years.

In the time between an outbreak and vaccine development, antivirals can play a vital role.

Antivirals: The Second Line of Defense in Virology

Antivirals are drugs that slow or prevent the growth of a virus and treat disease symptoms. They are especially important tools for diseases that do not have an associated vaccine.

In 2021, there were nearly six times as many approved antivirals as there were in 1995. Not only that, antiviral uses have grown to include the potential prevention and treatment of HIV, COVID-19, and a number of other diseases.

YearApproved Antivirals
in the U.S.
Reasons for
Using Antivirals
19951012
19961012
19971212
19981313
19991613
20001813
20011913
20022013
20032113
20042113
20052213
20062313
20072413
20082613
20092714
20102714
20113014
20123015
20133415
20143715
20154116
20164416
20174716
20184917
20194917
20205319
20215720

The potential prevention (prophylaxis) and treatment of the same virus are counted as separate uses. Data is cumulative and reflects all antivirals ever approved (and not taken off the market) and all reasons ever approved for using antivirals (that have not been rescinded).

Innovation in virology—and the potential for future developments—is leading to a growing industry.

Expanding Market Opportunities

With opportunities growing and approval times shortening, more companies are entering the market.

YearCompanies Developing Vaccines/Antivirals
199566
199673
199780
199881
199987
2000111
2001125
2002140
2003154
2004144
2005146
2006163
2007167
2008196
2009203
2010230
2011237
2012255
2013277
2014289
2015310
2016362
2017392
2018374
2019370
2020383
2021484

Data is a snapshot in time and reflects all companies developing vaccines or antivirals as of the noted year. If a company stops being active in the space or ceases to exist, they are removed from the total.

As they work to develop new vaccines and antivirals, companies are conducting clinical trials for many diseases beyond COVID-19 such as respiratory infections and sepsis.

Virology is leading to a number of groundbreaking technologies and therapies, transforming healthcare along the way.

Visual Capitalist Logo

Explore the MSCI Virology Index now.

Click for Comments

You may also like

Subscribe

Continue Reading

Subscribe

Popular